EUVIMEDEUVIMED entdecken
Open Access

Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations

Christina M Zettler, Dilanka L De Silva, Victoria S Blinder, Mark E Robson, Elena B Elkin

JAMA Network Open · 2024

DOI: 10.1001/jamanetworkopen.2023.50067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Christina M Zettler und 4 weiteren Autor:innen. Beteiligte Einrichtung: COTA Healthcare, New York, New York. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The OlympiA trial found that 1 year of adjuvant olaparib therapy can improve distant disease-free survival and overall survival from early-stage breast cancer in patients with a germline BRCA1/2 mutation. However, olaparib, an oral poly-adenosine diphosphate ribose polymerase inhibitor, is estimated to cost approximately $14 000 per month in the US.

Objective

To estimate the incremental cost-effectiveness of adjuvant olaparib compared with no olaparib in eligible patients. Design, Setting, and Participants In an economic evaluation from a health care system perspective, the cost-effectiveness of adjuvant olaparib was analyzed using a Markov state-transition model. The model simulated costs and lifetime health outcomes of 42-year-old women with high-risk early-stage breast cancer and a known BRCA1/2 mutation who completed definitive primary therapy and neoadjuvant or adjuvant systemic therapy. The study was conducted from August 2021 to July 2023. The effectiveness of olaparib was based on the findings of the OlympiA randomized clinical trial, and other model parameters were identified from the literature. The model was calibrated to the 1-, 2-, 3-, and 4-year distant disease-free and overall survival observed in the OlympiA trial, and olaparib was assumed to reduce the risk of distant recurrence only in the first 4 years. Exposure One year of adjuvant olaparib or no adjuvant olaparib. Main Outcome and Measure Incremental cost-effectiveness ratio (ICER) in 2021 US dollars per quality-adjusted life-year (QALY) gained. All outcomes were discounted by 3% annually.

Results

In the base case, adjuvant olaparib was associated with a 1.25-year increase in life expectancy and a 1.20-QALY increase at an incremental cost of $133 133 compared with no olaparib. The resulting ICER was approximately $111 000 per QALY gained. At a willingness-to-pay threshold of $150 000 per QALY, olaparib was cost-effective at its 2021 price and in more than 92% of simulations in probabilistic sensitivity analysis. The results were sensitive to assumptions about the effectiveness of olaparib and quality of life for patients with no disease recurrence. Conclusions and Relevance In this study, from a US health care system perspective, adjuvant olaparib was a cost-effective option for patients with high-risk, early-stage breast cancer and a germline BRCA1/2 mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAdultFemaleHumansBRCA1 ProteinBRCA2 ProteinCost-Benefit AnalysisGerm CellsMutationNeoplasm Recurrence, LocalQuality of LifeRandomized Controlled Trials as TopicPhthalazinesPiperazinesGold Alloys

Substanzen

BRCA1 ProteinBRCA2 ProteinBRCA1 protein, humanBRCA2 protein, humanolaparibPhthalazinesPiperazinesolympiaGold Alloys

Autor:innen und Institutionen

  • COTA Healthcare, New York, New York.
  • Peter MacCallum Cancer Centre, Parkville Familial Cancer Centre, Melbourne, Victoria, Australia.
  • Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Breast Medicine Service and Immigrant Health and Cancer Disparities Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Health Policy and Management, Columbia University Mailman School of Public Health, New York, New York.

Förderung

  • NCI NIH HHS

Zitieren

APA

Zettler, C. M., De Silva, D. L., Blinder, V. S., Robson, M. E., & Elkin, E. B. (2024). Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.50067

Vancouver

Zettler CM, De Silva DL, Blinder VS, Robson ME, Elkin EB. Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2023.50067

BibTeX
@article{Zettler2024,
  author = {Zettler, Christina M and De Silva, Dilanka L and Blinder, Victoria S and Robson, Mark E and Elkin, Elena B},
  title = {Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations},
  journal = {JAMA Network Open},
  year = {2024},
  doi = {10.1001/jamanetworkopen.2023.50067}
}
Kostenlos starten →